Abstract:BACKGROUND:People with fragile X syndrome (FXS) often have deficits in social behavior, and a substantial portion meet criteria for autism spectrum disorder. Though the genetic cause of FXS is known to be due to the silencing of FMR1, and the Fmr1 null mouse model representing this lesion has been extensively studied, the contributions of this gene and its protein product, FMRP, to social behavior are not well understood.METHODS:Fmr1 null mice and wildtype littermates were exposed to a social or non-social stimulus. In one experiment, subjects were assessed for expression of the inducible transcription factor c-Fos in response to the stimulus, to detect brain regions with social-specific activity. In a separate experiment, tissue was taken from those brain regions showing differential activity, and RNA sequencing was performed.RESULTS:Immunohistochemistry revealed a significantly greater number of c-Fos-positive cells in the lateral amygdala and medial amygdala in the brains of mice exposed to a social stimulus, compared to a non-social stimulus. In the prelimbic cortex, there was no significant effect of social stimulus; although the number of c-Fos-positive cells was lower in the social condition compared to the non-social condition, and negatively correlated with c-Fos in the amygdala. RNA sequencing revealed differentially expressed genes enriched for molecules known to interact with FMRP and also for autism-related genes identified in the Simons Foundation Autism Research Initiative gene database. Ingenuity Pathway Analysis detected enrichment of differentially expressed genes in networks and pathways related to neuronal development, intracellular signaling, and inflammatory response.CONCLUSIONS:Using the Fmr1 null mouse model of fragile X syndrome, we have identified brain regions, gene networks, and molecular pathways responsive to a social stimulus. These findings, and future experiments following up on the role of specific gene networks, may shed light on the neural mechanisms underlying dysregulated social behaviors in fragile X syndrome and more broadly.

Computational Identification and Experimental Validation of MicroRNAs Binding to the Fragile X Syndrome Gene Fmr1

Identification of Differentially Expressed Micrornas and Their Target Genes in the Hippocampal Tissues of Fmr1 Knockout Mice.

MicroRNA-130b Targets Fmr1 and Regulates Embryonic Neural Progenitor Cell Proliferation and Differentiation

Expressions of Drebrins and Lcam-5 in Mouse Cerebral Cortex with Fmr-1 Gene Knockout and Their Significance in Fragile X Syndrome

Systematic Validation of Predicted Micrornas for Cyclin D1

The Microrna Pathway and Fragile X Mental Retardation Protein

Regulation of Synaptic Structure and Function by FMRP-Associated MicroRNAs miR-125b and miR-132

Fragile X Mental Retardation Protein Modulates the Stability of Its M6a-Marked Messenger RNA Targets.

The molecular biology of FMRP: new insights into fragile X syndrome

Integrated Transcriptome Analysis of Human Ips Cells Derived from a Fragile X Syndrome Patient During Neuronal Differentiation

Cell-type-specific profiling of human cellular models of fragile X syndrome reveal PI3K-dependent defects in translation and neurogenesis

New perspectives on the biology of fragile X syndrome.

Identification of FMRP target mRNAs in the developmental brain: FMRP might coordinate Ras/MAPK, Wnt/β-catenin, and mTOR signaling during corticogenesis

MiR-219 Represses Expression of Dfmr1 in Drosophila Melanogaster.

Identification of Fragile X Syndrome Specific Molecular Markers in Human Fibroblasts: A Useful Model to Test the Efficacy of Therapeutic Drugs

MicroRNA-129 modulates neuronal migration by targeting Fmr1 in the developing mouse cortex

Effects of a Social Stimulus on Gene Expression in a Mouse Model of Fragile X Syndrome.

The Study of FXR1P-Interacting Mrna

MiR-315 is Required for Neural Development and Represses the Expression of Dfmr1 in Drosophila Melanogaster

Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene.

Computational analysis of transcriptome signature repurposes low dose trifluoperazine for the treatment of fragile X syndrome in mouse model